PCI Pharma Services Announces UK Facility Expansion

PCI Pharma Services, a pharmaceutical and biopharmaceutical outsourcing solutions provider based in Philadelphia, PA, announced on Dec. 11, 2019 that an expansion of its Tredegar facility in Wales, United Kingdom is underway. The expansion plans to build upon the company’s high potent drug manufacturing and development capabilities, including both clinical and commercial supply.

Set to be completed by late 2021, the expansion will double the facility’s large-scale granulation and fluid bed drying capacity, create additional space for new potent handling capabilities, and will add an analytical and a small-scale processing area for early stage non-GMP processing and formulation, according to a company press release.

“Pharmaceutical and biopharmaceutical companies are innovating drug treatments today at a rapid pace and in greater volume. As the market continues to grow, we’ve seen an increasing number of clients look to us to provide manufacturing services across the spectrum of dosage forms,” said Richard Yarwood, chief scientific officer, PCI Pharma Services, in the press release. “The expansion at Tredegar will double our large-scale manufacturing capacity to ensure that new and existing customers have their development and supply needs met now and in the future.”

The new expansion comes after the company completed an expansion on its Rockford, IL, facility on Dec. 4, 2019 to enhance its specialty drug product capabilities.

“This latest investment in Tredegar is part of our ongoing business strategy to remain flexible in an ever-changing marketplace to better service our clients as they work to deliver life-changing therapies to patients, such as key oncology compounds which require high potent processing expertise,” said Salim Haffar, CEO, PCI Pharma Services, in the press release. “Growing our manufacturing capabilities in Tredegar demonstrates our commitment to manufacturing and providing this service to clients who need a supply chain partner throughout the entire process, from drug development to commercialization.”

Source: PCI